Our earlier study demonstrated that ADT activates ZBTB46, a prostatic tumor promoter, which promotes the epithelial–mesenchymal transition through transcriptional regulation of SNAI123 and is associated with neuroendocrine differentiation and tumor recurrence in prostate cancer after ADT24. This evidence concerns the gene ZBTB46 and prostate cancer.